Unlike GLP-1 agonists, it preserves lean muscle mass during caloric restriction
In developing regions, this financial barrier is even more pronounced, slowing market penetration despite growing obesity prevalence While efforts are underway to improve affordabilityincluding the introduction of generic formulations and price negotiations in certain marketsthe perception of GLP-1 therapies as premium, high-cost treatments can deter both patients and providers from widespread adoption Overcoming these challenges through the development of cost-effective alternatives, enhanced insurance support, and patient assistance programs will be vital for ensuring sustained and inclusive market growth in the GLP-1 receptor agonists obesity drugs market GLP-1 Receptor Agonists Obesity Drugs Market Scope The market is segmented on the basis of drug type, route of administration, application, and distribution channel
Gentle reconstitution helps keep the peptide stable during the first few minutes
Primarily, treatment in T2DM is pharmacologically tried by using drugs that are insulin sensitizers, insulin secretagogues, -glucosidase inhibitors, and glucose transporter inhibitors
Animal studies raised thyroid Ccell proliferation concerns